AO-176

· Arch Oncology

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AO-176, covering 2023-08-22 to 2023-08-22. Get the full timeline:

Most recent: Clinical Trial Update: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing